Core Viewpoint - Aquestive Therapeutics has successfully completed a Type A meeting with the FDA regarding the resubmission of its New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film, aimed at treating Type 1 allergic reactions, including anaphylaxis [1][2] Group 1: FDA Interaction and Study Design - The Type A meeting confirmed the company's approach on key program elements and received clarifying feedback on pharmacokinetic (PK) and human factors (HF) study designs [2][7] - The FDA provided preliminary comments on the PK study design, focusing on consistency with past studies, and the company plans to address this feedback [2][3] - The FDA recommended changes to user groups in the HF study design, and the company believes there is alignment on key elements following discussions during the meeting [3] Group 2: Product Details and Market Potential - Anaphylm™ is a polymer matrix-based epinephrine prodrug that is designed for easy administration without the need for water or swallowing, making it a unique oral epinephrine rescue medication [5] - The product is expected to be the first and only FDA-approved, non-invasive, orally delivered epinephrine product for severe allergic reactions, which could transform treatment options for patients at risk [4][8] Group 3: Future Plans and Regulatory Submissions - The company reaffirms its guidance to resubmit the Anaphylm NDA in the third quarter of 2026 and is also advancing regulatory submissions in Canada and the European Union [4][7] - The company is preparing for human factors and pharmacokinetic studies to support the planned NDA resubmission [2][4]

Core Insights - Aquestive Therapeutics is advancing Anaphylm, the first oral epinephrine rescue medication, towards global approval, emphasizing its transformative potential for patients with severe allergies [2][3] - The company plans to address deficiencies identified by the FDA in a Complete Response Letter (CRL) and aims to resubmit the New Drug Application (NDA) in Q3 2026 [4][6] - Financial results for Q4 2025 show a revenue increase to $13.0 million, driven by manufacturing and supply revenue, while the net loss was $31.9 million, influenced by higher legal and commercial expenses [21][24] Company Developments - Anaphylm is positioned as a non-invasive, orally delivered epinephrine product, with the potential to be the first of its kind if approved by the FDA [3] - The company has strengthened its leadership by appointing Dr. Greenhawt as Chief Medical Officer, enhancing its expertise in allergy and immunology [2] - A Type A meeting with the FDA has been requested to discuss the resubmission process for Anaphylm, with plans for parallel human factors validation and pharmacokinetics studies [6] Financial Performance - Total revenues for Q4 2025 increased by 10% to $13.0 million compared to Q4 2024, primarily due to higher manufacturing and supply revenue [21] - Research and development expenses decreased to $3.2 million in Q4 2025, reflecting reduced clinical trial costs associated with Anaphylm [22] - Selling, general, and administrative expenses rose significantly to $32.8 million in Q4 2025, largely due to increased legal expenses and preparations for Anaphylm's launch [23] Market Strategy - The company is advancing its global expansion strategy for Anaphylm, with ongoing regulatory engagement in Canada and the EU [7] - Plans for the launch of Anaphylm focus on optimizing market access and increasing awareness through medical affairs strategies [8] - The company expects to end FY2026 with cash and cash equivalents of $70 million, supporting its operational and developmental activities [8][33] Product Pipeline - AQST-108, a topical epinephrine gel for alopecia areata, is in clinical trials, with positive initial results and potential for significant market share if approved [10][12] - The company continues to manufacture products for various collaborations, maintaining steady production levels despite the decline of Suboxone revenues [14] Future Outlook - For FY2026, the company projects total revenue between $46 million and $50 million, with a non-GAAP adjusted EBITDA loss guidance of $30 million to $35 million [33] - The financial outlook includes costs related to the resubmission of Anaphylm's NDA and ongoing clinical trials for AQST-108 [33]

Core Viewpoint - Aquestive Therapeutics announced the investigational use of Anaphylm™ (dibutepinephrine) sublingual film, which achieved clinically relevant epinephrine plasma concentrations without causing a dip in diastolic blood pressure, highlighting its potential to transform anaphylaxis management [1][2]. Group 1: Product Details - Anaphylm™ is a polymer matrix-based epinephrine prodrug that is small, lightweight, and dissolves on contact, requiring no water or swallowing for administration [3]. - The product's packaging is designed to be portable and weather-resistant, making it easy to carry in a wallet or phone [3]. - If approved by the FDA, Anaphylm would be the first oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis [3]. Group 2: Clinical Data and Presentations - Multiple poster presentations at the 2026 AAAAI Annual Meeting will showcase the clinical data for Anaphylm, emphasizing its differentiated profile and potential for meaningful outcomes [2]. - Key findings include the absence of a diastolic blood pressure dip following sublingual administration, which is a significant clinical concern in anaphylaxis treatment [2]. Group 3: Company Overview - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, operating as both a product developer and a Contract Development and Manufacturing Organization (CDMO) [5]. - The company has a portfolio that includes four commercialized products and a library of over 20 epinephrine prodrugs for various allergy and dermatological indications [5].

Core Viewpoint - Aquestive Therapeutics has appointed Dr. Matthew Greenhawt as Chief Medical Officer to support the resubmission of the Anaphylm™ New Drug Application (NDA) and advance its clinical pipeline [1][2][3] Company Leadership and Expertise - Dr. Greenhawt is an internationally recognized expert in allergy and immunology, bringing extensive clinical, research, and advocacy experience to the company at a critical time [2][4] - The appointment is seen as a strong addition to the leadership team, with Dr. Greenhawt's expertise expected to be invaluable for FDA approval efforts [3] Product Development - Anaphylm™ (dibutepinephrine) is a sublingual film designed for the emergency treatment of anaphylaxis, which is expected to be the first oral medication for severe allergic reactions if approved by the FDA [7] - The product is designed to be user-friendly, dissolving on contact without the need for water or swallowing, and is compact enough to be carried easily [7] Company Background - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, operating as both a product developer and a Contract Development and Manufacturing Organization (CDMO) [8] - The company has a portfolio that includes four commercialized products and is advancing multiple product candidates, including Anaphylm and AQST-108 for various indications [8]

Core Insights - Aquestive Therapeutics is progressing towards the potential launch of Anaphylm, an innovative sublingual film for treating severe allergic reactions, with a scheduled PDUFA goal date of January 31, 2026 [2][4] - The company is expanding its commercial readiness and regulatory discussions in the U.S., Canada, and the EU, aiming to enhance patient access to epinephrine treatments [5][6] - Financial results for Q3 2025 show a 4% year-over-year revenue increase, although total revenues decreased from $13.5 million in Q3 2024 to $12.8 million in Q3 2025 due to prior year deferred revenue recognition [13][17] Financial Performance - Total revenues for Q3 2025 were $12.8 million, a decrease from $13.5 million in Q3 2024, primarily due to the one-time recognition of deferred revenue in the previous year [13] - Manufacture and supply revenue increased to $11.5 million in Q3 2025 from $10.7 million in Q3 2024, driven by growth in Sympazan and Suboxone revenues [14] - Net loss for Q3 2025 was $15.4 million, or $0.14 per share, compared to a net loss of $11.5 million, or $0.13 per share, in Q3 2024 [17] Product Development - Anaphylm, if approved, would be the first oral medication for severe allergic reactions, designed to improve patient compliance and accessibility [3][22] - The company is also advancing AQST-108, a topical epinephrine gel for alopecia areata, with an IND application expected to be submitted in Q4 2025 [7][24] - Recent patent expansions for Anaphylm extend protection into 2037, highlighting the product's long-term commercial potential [6] Strategic Initiatives - The company is enhancing its commercial and medical infrastructure in preparation for a potential U.S. launch of Anaphylm in Q1 2026 [5] - Strategic funding commitments and equity financing have positioned the company to support its mission of making epinephrine treatments more accessible [2] - The addition of new leadership for the AdrenaVerse clinical pipeline indicates a commitment to developing further products from this technology platform [8]

Core Insights - Aquestive Therapeutics, Inc. is hosting a live fireside chat on November 6, 2025, focusing on its product candidate Anaphylm™ (dibutepinephrine) Sublingual Film, discussing regulatory progress and commercial readiness [1][2] Company Overview - Aquestive Therapeutics is a pharmaceutical company dedicated to improving patients' lives through innovative science and delivery technologies, developing orally administered products to deliver complex molecules [5] - The company has four commercialized products marketed by its licensees globally and collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies like PharmFilm® [5] Product Details - Anaphylm™ (dibutepinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug that is designed to be administered without water or swallowing, making it user-friendly [4] - If approved by the FDA, Anaphylm would be the first oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis, with its trade name conditionally approved [4]

Core Viewpoint - Aquestive Therapeutics has received two additional U.S. patents for Anaphylm, extending its protection until at least 2037, which reinforces its position in the market for treating severe allergic reactions [1][2][7]. Patent Protection - The newly issued patents include U.S. patent number 12,427,121 and U.S. patent number 12,443,850, which cover the proprietary composition for Anaphylm, an epinephrine prodrug sublingual film [2][3]. - These patents are part of a broader intellectual property strategy that includes multiple pending and planned patent applications across various continents [2]. Product Overview - Anaphylm is designed as a device-free, sublingual film that offers a patient-friendly alternative to traditional epinephrine injections, addressing the fear of needles among patients [3][4]. - The product is small, lightweight, and begins to dissolve upon contact, requiring no water or swallowing for administration [4]. Regulatory Timeline - The Prescription Drug User Fee Act (PDUFA) target action date for Anaphylm is set for January 31, 2026, pending FDA approval [3][6]. Company Background - Aquestive Therapeutics focuses on advancing innovative medicines through proprietary technologies, including PharmFilm and Adrenaverse™, to improve patient care [5]. - The company has four commercialized products and collaborates with other pharmaceutical companies to bring new molecules to market [5].

Core Viewpoint - Aquestive Therapeutics has announced that the FDA has determined that an advisory committee meeting is not required for the approval of Anaphylm™ (dibutepinephrine) Sublingual Film, with a target action date set for January 31, 2026 [1][7]. Product Overview - Anaphylm has the potential to be the first FDA-approved, non-invasive, orally delivered epinephrine product for treating severe allergic reactions, including anaphylaxis [2][3]. - The product is designed as a thin, dissolvable film that is placed under the tongue, offering a device-free and needle-free option for patients at risk of severe allergic reactions [2][3]. - Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve upon contact, requiring no water or swallowing for administration [4]. Clinical Development - Eleven clinical studies have been completed, totaling 967 administrations (840 single-dose and 127 repeat-dose) for adults and children over 30 kg [3]. - The development program includes a novel trial for oral allergy syndrome, demonstrating Anaphylm's real-world effectiveness [3]. Company Positioning - The company is well-positioned for the launch of Anaphylm, supported by recent financing activities totaling $160 million, which will facilitate outreach to healthcare providers, caregivers, and patients post-FDA approval [3]. - Aquestive Therapeutics is focused on advancing medicines through innovative science and delivery technologies, with four commercialized products marketed globally [5].

Core Insights - Aquestive Therapeutics, Inc. announced two poster presentations on Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit, highlighting its potential as the first orally delivered epinephrine option for severe allergic reactions in the U.S. [1] Group 1: Product Details - Anaphylm™ is a polymer matrix-based epinephrine prodrug that is small, lightweight, and dissolves on contact without the need for water or swallowing [3] - The product's packaging is designed to be portable and weather-resistant, making it convenient for users [3] - Anaphylm has received conditional approval for its trade name from the FDA, pending final product approval [3] Group 2: Presentation Information - The first poster presentation focuses on the physicochemical properties of Anaphylm under extreme temperatures and real-world conditions, led by Nils Confer, PhD [2] - The second poster presentation discusses the pharmacokinetic and pharmacodynamic responses of Anaphylm, led by Carl Kraus, MD [2] Group 3: Company Overview - Aquestive Therapeutics is dedicated to advancing medicines through innovative science and delivery technologies, with a focus on orally administered products [4] - The company has four commercialized products and collaborates with other pharmaceutical companies to bring new molecules to market [4] - In addition to Anaphylm, the company is developing an earlier-stage epinephrine prodrug topical gel for dermatological conditions [4]

Core Insights - Aquestive Therapeutics announced positive topline results from its pediatric study for Anaphylm™ (epinephrine) sublingual film, indicating its potential as a treatment for severe allergic reactions in patients aged seven to seventeen [1][2] - The company has submitted the New Drug Application (NDA) for Anaphylm to the FDA, with expectations for acceptance in the second quarter of 2025 [1][6] - If approved, Anaphylm is planned to be launched in the first quarter of 2026 [2] Pediatric Study Results - The pediatric study was a multi-site, single treatment study involving thirty-two patients, demonstrating consistent pharmacokinetic (PK) profiles with previous adult studies [2] - Anaphylm was found to be safe and well-tolerated, with no serious adverse events reported [2] Product Overview - Anaphylm is a polymer matrix-based epinephrine prodrug designed for the treatment of severe allergic reactions, including anaphylaxis [3] - The product is compact, similar in size to a postage stamp, and does not require water or swallowing for administration [3] Company Background - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, with five commercialized products and collaborations with other pharmaceutical companies [4] - The company is also developing an earlier stage epinephrine prodrug topical gel for dermatological conditions [4]